Novelix Pharmaceuticals Ltd signs Technology Transfer agreement GMBU e.V., Germany for Large-Scale of Astaxanthin

Novelix Pharmaceuticals Limited (BSE: NOVELIX | 536565 | INE314I01036) announced today that it has signed a Technology Transfer agreement with GMBU e.V., Germany, marking a strategic collaboration to advance the large-scale production of Astaxanthin, a potent antioxidant with broad nutraceutical and pharmaceutical applications.

Under the agreement, GMBU e.V. will transfer its proprietary technology, expertise, and technical support services for the cultivation and scale-up of Haematococcus pluvialis to Novelix's state-of-the-art laboratories at BTIC Park, Genome Valley, Hyderabad. The collaboration aims to bring Astaxanthin to market at a commercial scale for global supply.

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program, including the provision of algal strains, media components, laboratory equipment, and infrastructure. The company will also establish a GMP-certified production facility at its Techno Park site in Hyderabad to manufacture Astaxanthin in bulk, targeting key markets across Europe, North America, and India.

Dr. Enrico Ehrhardt, Head of the Department of Molecular Biology, GMBU e.V., Germany, commented: "This is a significant milestone for GMBU e.V. as we partner with Novelix Pharmaceuticals Limited, a leading Indian pharmaceutical company, for the development and scale-up of Haematococcus pluvialis. We believe this collaboration will open new avenues for joint innovation across biotechnology and healthcare domains, ensuring affordable access to highquality therapeutic products."

Mr. Gattu Gyan Prakash, Director, Novelix Pharmaceuticals Limited, stated: "We are thrilled to collaborate with GMBU e.V., Germany, to bring Astaxanthin production to India. This compound has tremendous therapeutic potential and commercial promise as a nutraceutical. Beyond product development, this partnership symbolizes a robust Indo-German collaboration model in biotechnology and life sciences. Novelix remains committed to advancing transformative, affordable healthcare solutions - from novel drug discovery and medical diagnostics to therapeutics and biomedical devices."

Shares of Novelix Pharmaceuticals Ltd was last trading in BSE at Rs. 42.05 as compared to the previous close of Rs. 40.08. The total number of shares traded during the day was 12982 in over 21 trades.

The stock hit an intraday high of Rs. 42.08 and intraday low of 40.00. The net turnover during the day was Rs. 540795.00.

Source : Equity Bulls

Keywords

NovelixPharmaceuticals INE314I01036 TechnologyTransferAgreement GMBUeV Germany Astaxanthin